Hummingbird Bioscience
PrivateLast Round
Series C
May 18, 2021
Total Funding Raised
$182.1M
Company Overview
Hummingbird Bioscience is a biotechnology company that develops innovative therapeutic antibody-based drugs aimed at addressing the significant unmet needs of oncology and immuno-oncology patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hummingbird Bioscience Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Hummingbird Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 18, 2021 | ||||
| Series B Extension | May 10, 2020 | ||||
| Series B | Dec 4, 2019 | ||||
| Series A Extension | Jul 10, 2019 | ||||
| Grant | Feb 21, 2019 | ||||
Series A | May 3, 2017 |
Key People
Founding team and executive leadership
Hummingbird Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heritas Capital Management | Series B, Series C, Series B Extension, Series A Extension |
| Cancer Prevention & Research Institute of Texas | Grant |
| Frazier Healthcare Partners | Series C |
| SEEDS Capital | Series B, Series C, Series B Extension, Series A Extension |
| Mirae Asset | Series B, Series C |
| Octagon Capital Advisors | Series C |
| Ally Bridge Group | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 15, 2025
Clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity.
- May 18, 2021
$125M round led by Novo Holdings.
Hummingbird Bioscience Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Hummingbird Bioscience's valuation, stock price, and market status.